MoonLake Immunotherapeutics (MLTX) Change in Cash (2021 - 2026)

MoonLake Immunotherapeutics' Change in Cash history runs 6 years deep, the most recent figure standing at -$36.0 million for Q1 2026.

• In Q1 2026, Change in Cash fell 139.53% year-over-year to -$36.0 million; the TTM figure through Mar 2026 stood at $26.9 million (up 114.41% YoY), while the FY2025 annual figure was $154.1 million, up 156.91% from the prior year.
• Change in Cash for Q1 2026 stood at -$36.0 million, down from -$16.2 million in the prior quarter.
• The five-year high for Change in Cash was $451.7 million in Q2 2023, with the low at -$195.2 million in Q4 2024.
• The 5-year median for Change in Cash is $7.3 million (2024), against an average of $17.1 million.
• The sharpest annual moves came in 2022 and 2023: Change in Cash tumbled 3259.8% in 2022, then surged 7928.12% in 2023.
• MoonLake Immunotherapeutics' Change in Cash stood at -$1.7 million in 2022, then soared by 7928.12% to $133.0 million in 2023, then sank by 246.79% to -$195.2 million in 2024, then surged by 91.69% to -$16.2 million in 2025, then tumbled by 122.13% to -$36.0 million in 2026.
• Business Quant data shows MLTX's Change in Cash at -$36.0 million in Q1 2026, -$16.2 million in Q4 2025, and $44.1 million in Q3 2025.